Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast for inhibition of atherosclerosis progression and restenosis after endovascular treatment in peripheral arterial disease
2024-511894-32-00Phase 3Completed
- Sponsor
- Jagiellonian University Medical College
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of montelukast in peripheral artery occlusion (PAD), sponsored by Jagiellonian University Medical College. Primary endpoint: Restenosis in a previously treated artery. Started Jul 2024; status: completed.
02
Drugs
montelukast
03
Conditions
peripheral artery occlusion (PAD)
Beyond the preview
Go deeper on 2024-511894-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511894-32-00.